

27 March 2024

Appendix 3Y – Beth Kaplan

Shekel Brainweigh (ASX: SBW, “Company”) provides the attached Appendix 3Y for Beth Kaplan.

The Company notes that this notice was not lodged within the required time frame due to an administrative oversight. The Company took immediate action to complete and lodge this Appendix 3Y as soon as it became aware of the oversight.

The Company and Directors are aware of the requirements under the ASX Listing Rules and the Company considers this an isolated incident.

This announcement has been approved for release by the Company Secretary.

-ENDS-

Investor and media enquiries:

Danny Nadri
Country Manager – Australia
+61 (0)434 680 391
danny@shekel.ai

Barak Nir
CFO
+972 50 538 6090
barak@shekel.ai

About Shekel Brainweigh (“Shekel” or “the Company”)

Shekel is a global leader in developing scale and weighing technology. The company provides weighing solutions to the highly regulated retail and healthcare markets via global giants such as G.E Healthcare, Toshiba, Fujitsu, Diebold Nixdorf and others.

Utilising its experience in weighing technology, Shekel has established its Retail Innovation suite of products, which is aimed at meeting the challenges that traditional retailers face today, such as store automation, operational efficiency including overstock and understock inventory issues and enhancing the consumer experience.

Shekel’s patented combination of weighing technology with Artificial Intelligence (AI) has led to the development of its “Product Aware Technology”.
Shekel is committed to continuing to innovate and expand into global markets.

To learn more about Shekel Brainweigh, visit www.shekelbrainweigh.com

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Shekel Brainweigh Ltd
ARBN	625 669 445

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Beth Kaplan
Date of last notice	3 December 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Axcel Partners VI LLC
Date of change	24 August 2023
No. of securities held prior to change	Axcel Partners VI LLC 53,304,505 Fully Paid Ordinary Shares
Class	Fully Paid Ordinary Shares
Number acquired	Nil
Number disposed	167,028
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$58,460
No. of securities held after change	Axcel Partners VI LLC 53,137,477 Fully Paid Ordinary Shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off-market trade
---	------------------

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.